Two-target antibody–drug therapy for advanced prostate cancer
Develop novel bispecific antibody-drug conjugates against metastatic lethal prostate cancer across subtype
Creating two-target antibody–drug medicines for people with advanced metastatic prostate cancer to improve how well treatments reach and kill tumor cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11303292 on NIH RePORTER |
What this research studies
Researchers will design bispecific antibody–drug conjugates that bind two prostate tumor markers (including CD46, B7-H3, and DLL3) to overcome tumor variability. They will test these bispecific ADCs in lab assays and animal models to measure tumor uptake, internal delivery, and anti-tumor activity compared with single-target ADCs. The team builds on a CD46-directed ADC (FOR46) that has already entered early human trials and will use those clinical data to guide design. Promising candidates would be prepared for safety testing and future clinical trial development at UCSF and partner centers.
Who could benefit from this research
Good fit: Ideal candidates would be people with metastatic, treatment-resistant prostate cancer (for example mCRPC) whose tumors express one or more of the targeted proteins such as CD46, B7-H3, or DLL3.
Not a fit: People with early-stage localized prostate cancer or tumors that lack these target proteins are unlikely to benefit from this therapy.
Why it matters
Potential benefit: If successful, this approach could produce more effective targeted treatments that better kill metastatic prostate cancer cells across different tumor subtypes.
How similar studies have performed: Single-target ADCs like the CD46-directed FOR46 have shown good tolerability and early efficacy signals in phase I/II testing, while bispecific ADCs are a newer concept not yet proven in prostate cancer.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Liu, Bin — University of California, San Francisco
- Study coordinator: Liu, Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.